The Global Vascular Closure Devices Market Size is projected to grow at a CAGR of 5.70% during the forecast period from 2026 to 2034 | DelveInsight

DelveInsight's Vascular Closure Devices Market Insights Report 2034 provides the current and forecast market analysis, individual leading Vascular Closure Devices Companies market shares, challenges, Vascular Closure Devices Market Drivers, barriers, trends, and key market Vascular Closure Devices companies in the market.

To read more about the latest highlights related to the Vascular Closure Devices Market @ https://www.delveinsight.com/sample-request/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Vascular Closure Devices Market Report
• In January 2026, Haemonetics Corporation acquired Vivasure Medical for a reported USD 116 million upfront, expanding into large-bore structural heart and endovascular closure through the fully bioresorbable, sutureless PerQseal platform. Strategic significance: the acquisition gave a growing closure specialist a leading fully bioresorbable large-bore platform and a foothold in the fastest-growing segment of the market, consolidating large-bore closure among the larger players and intensifying competition for the structural heart opportunity.
• In June 2025, Vivasure Medical announced that it had received European CE Mark approval for an expanded indication for its fully bioresorbable, sutureless PerQseal Elite, covering large-bore venous closure. Strategic significance: the expansion of a fully bioresorbable sutureless device into large-bore venous closure addressed the growing volume of transcatheter mitral and tricuspid and other venous structural heart procedures, extending the reach of bioresorbable technology into a new and expanding segment.
• In May 2025, Zylox-Tonbridge Medical secured regulatory clearance for its ZYLOX Unicorn vascular closure device in Indonesia, marking its first international approval and first Southeast Asian market entry. Strategic significance: the international expansion of an emerging manufacturer into Southeast Asia illustrated the growing role of regional and cost-competitive players in extending access to closure devices across price-sensitive Asia-Pacific markets and intensifying global competition.
• In March 2025, Vasorum USA Inc. received U.S. Food and Drug Administration approval for its Celt ACD Plus System, a next-generation small-bore arterial closure device designed to enhance procedural outcomes. Strategic significance: The United States approval of a next-generation small-bore arterial closure device broadened the competitive field in the large small-bore segment and reflected continued innovation in the routine diagnostic and interventional closure that constitutes the majority of procedure volume.
• In February 2025, Teleflex Incorporated entered into a definitive agreement to acquire the Biotronik vascular intervention business, complementing its MANTA large-bore closure device with a broader interventional portfolio. Strategic significance: the acquisition strengthened the interventional and structural heart position of a leading large-bore closure player, aligning closure with a wider vascular intervention portfolio and reinforcing the strategic importance of large-bore closure to the structural heart opportunity.
• The global vascular closure devices market was valued at USD 1.64 billion in 2025 and is projected to reach USD 2.70 billion by 2034.
• The market is expected to expand at a CAGR of 5.70% during the forecast period 2026-2034, supported by the rising prevalence of cardiovascular disease, the growing adoption of minimally invasive catheter-based procedures, the expansion of large-bore structural heart interventions, and continuous technological advancement in closure devices.
• The principal drivers are the rising prevalence of cardiovascular disease, with DelveInsight estimating some 26 million cases of atherosclerotic cardiovascular disease across the seven major markets in 2023; the large and growing diabetic population, estimated at some 590 million adults worldwide in 2024; the growing adoption of minimally invasive procedures; the rapid expansion of large-bore structural heart interventions such as transcatheter aortic valve replacement and endovascular aneurysm repair; the shift toward same-day-discharge care; and continuous advancement in bioabsorbable and large-bore closure.
• The leading Vascular Closure Devices Companies include Abbott, Teleflex Incorporated, Terumo Medical Corporation, Cardinal Health, Cardival Medical, Inc., Merit Medical Systems, Medtronic, Morris Innovative, TZ Medical, Vasorum Ltd, Tricol Biomedical, Vivasure Medical Ltd, Transluminal Technologies, W. L. Gore & Associates, Inc., Meril Life Sciences Pvt. Ltd., Gem Srl and others.

To know more about why North America is leading the market growth in the Vascular Closure Devices Market, Get a snapshot @ https://www.delveinsight.com/sample-request/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Vascular Closure Devices Overview
Vascular closure devices (VCDs) are specialized medical devices used to achieve rapid hemostasis (the stopping of bleeding) at the site of arterial or venous puncture following minimally invasive procedures such as cardiac catheterization, angiography, and endovascular interventions. These devices are designed to seal the access site after the removal of a catheter or sheath, reducing the need for prolonged manual compression. Vascular closure devices work through various mechanisms, including collagen plugs, suture-mediated closure, clips, or sealants, to promote vessel closure and accelerate healing. Compared with manual compression, VCDs can shorten the time to hemostasis, enable earlier patient ambulation, improve patient comfort, and enhance procedural efficiency. They are widely used in interventional cardiology, radiology, and vascular surgery, particularly for procedures requiring femoral artery access, although devices for radial artery access are also becoming increasingly available.

Vascular Closure Devices Market Key Growth Drivers
• Rising prevalence of cardiovascular disease, with DelveInsight estimating that the seven major markets accounted for some 26 million cases of atherosclerotic cardiovascular disease in 2023, projected to rise further by 2034.
• A large and growing diabetic population, with DelveInsight estimating that some 590 million adults aged 20 to 79 were living with diabetes worldwide in 2024, projected to reach 854 million by 2050, which sharply elevates cardiovascular risk.
• Growing adoption of minimally invasive catheter-based procedures such as angiography, angioplasty, and stenting that require arterial access and closure.
• The rapid expansion of large-bore structural heart procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair, which require dedicated large-bore closure.
• The shift toward outpatient and same-day-discharge procedures, which vascular closure devices facilitate by shortening time to hemostasis and enabling earlier ambulation.
• Continuous technological advancement, including bioabsorbable materials, large-bore closure systems, and next-generation suture-based and sealant devices.
• Rising product development and regulatory approval activity among the leading manufacturers, broadening the range of closure solutions.

Get a sneak peek at the Tele Vascular Closure Devices Market Dynamics @ https://www.delveinsight.com/sample-request/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Vascular Closure Devices Market Segment Analysis
The global vascular closure devices market is segmented by closure mechanism (suture-mediated devices, collagen-plug devices, sealant and gel-based devices, clip-based devices, and dedicated large-bore closure devices), by access site (femoral and radial), by sheath size (small-bore and large-bore), by end-user (hospitals and clinics, ambulatory surgical centers, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

Vascular Closure Devices Market Competitive Landscape
The global vascular closure devices market is classified as Moderately Consolidated. A small group of large medical technology companies, including Abbott, Terumo, Cardinal Health through Cordis, and Teleflex, dominates through strong brand presence, broad closure portfolios, and global distribution networks, while smaller companies drive innovation with bioabsorbable and specialized large-bore and venous closure solutions, often leading to acquisition by the larger firms. Competition centers increasingly on large-bore closure for procedures such as transcatheter aortic valve replacement and endovascular aneurysm repair, where dedicated technologies are becoming critical, and strategic mergers, partnerships, and geographic expansion into high-growth regions intensify the contest. The competitive landscape is evaluated across the following dimensions:

Which MedTech key players in the Vascular Closure Devices Market are set to emerge as the trendsetter explore @ https://www.delveinsight.com/sample-request/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Vascular Closure Devices Companies
Abbott, Teleflex Incorporated, Terumo Medical Corporation, Cardinal Health, Cardival Medical, Inc., Merit Medical Systems, Medtronic, Morris Innovative, TZ Medical, Vasorum Ltd, Tricol Biomedical, Vivasure Medical Ltd, Transluminal Technologies, W. L. Gore & Associates, Inc., Meril Life Sciences Pvt. Ltd., Gem Srl and others.

Vascular Closure Devices Market Restraints
Despite a growing and broadly based demand, the vascular closure devices market faces material constraints that temper the pace of adoption. The most significant is the risk of complications associated with closure devices themselves. While these devices reduce the time to hemostasis and support early ambulation, they carry risks including bleeding, hematoma, vessel injury, infection, pseudoaneurysm, and arterial occlusion, and device failure can necessitate manual compression, surgical repair, or further intervention. These risks can lead to serious patient harm, increased healthcare costs, and a cautious approach among clinicians, some of whom continue to prefer manual compression in selected patients, and they underscore the clinical demand for safer materials and designs even as they constrain adoption of existing ones. The second constraint is the stringent regulatory standard imposed by authorities such as the United States Food and Drug Administration and the European Union Medical Device Regulation.

Interested in knowing the Vascular Closure Devices Market by 2034? Click to get a snapshot of the Vascular Closure Devices Market Trends- https://www.delveinsight.com/sample-request/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Vascular Closure Devices Market Report
• Coverage- Global
• Forecast Period- 2026-2034
• Vascular Closure Devices Companies- Abbott, Teleflex Incorporated, Terumo Medical Corporation, Cardinal Health, Cardival Medical, Inc., Merit Medical Systems, Medtronic, Morris Innovative, TZ Medical, Vasorum Ltd, Tricol Biomedical, Vivasure Medical Ltd, Transluminal Technologies, W. L. Gore & Associates, Inc., Meril Life Sciences Pvt. Ltd., Gem Srl and others.
• Vascular Closure Devices Market Restraints and Regulatory Analysis
• Vascular Closure Devices Porter Five Forces Analysis and Market Assessment

Explore more information of the Vascular Closure Devices Market Insights @ https://www.delveinsight.com/sample-request/vascular-closure-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Vascular Closure Devices Market Report Introduction
2. Vascular Closure Devices Market Executive Summary
3. Vascular Closure Devices Competitive Landscape
4. Vascular Closure Devices Regulatory Analysis
5. Vascular Closure Devices Market Key Factors Analysis
6. Vascular Closure Devices Market Porter's Five Forces Analysis
7. Vascular Closure Devices Market Assessment
8. Vascular Closure Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.